1. Home
  2. CANG vs CRDF Comparison

CANG vs CRDF Comparison

Compare CANG & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cango Inc.  each representing two (2)

CANG

Cango Inc. each representing two (2)

HOLD

Current Price

$0.29

Market Cap

116.5M

Sector

Technology

ML Signal

HOLD

Logo Cardiff Oncology Inc.

CRDF

Cardiff Oncology Inc.

HOLD

Current Price

$1.56

Market Cap

114.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CANG
CRDF
Founded
2010
1999
Country
United States
United States
Employees
96
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
116.5M
114.2M
IPO Year
2018
2012

Fundamental Metrics

Financial Performance
Metric
CANG
CRDF
Price
$0.29
$1.56
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
4
Target Price
$3.00
$9.63
AVG Volume (30 Days)
816.5K
1.7M
Earning Date
05-14-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
27.37
EPS
N/A
N/A
Revenue
N/A
$365,993.00
Revenue This Year
$428.72
N/A
Revenue Next Year
$18.39
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
49.61
52 Week Low
$0.29
$1.35
52 Week High
$5.75
$4.56

Technical Indicators

Market Signals
Indicator
CANG
CRDF
Relative Strength Index (RSI) 30.73 48.15
Support Level N/A $1.49
Resistance Level $0.50 $1.76
Average True Range (ATR) 0.05 0.16
MACD -0.01 -0.01
Stochastic Oscillator 0.93 37.69

Price Performance

Historical Comparison
CANG
CRDF

About CANG Cango Inc. each representing two (2)

Cango Inc is a Bitcoin mining company with a vision to establish an integrated, world-wide infrastructure platform capable of powering the future digital economy. The operations are divided into two reportable segments (i) Bitcoin Mining Business and (ii) International Automobile Trading Business. The Company's mining operations span over 40 sites across North America, the Middle East, South America, and East Africa. Since entering the digital asset space in November 2024, Cango has activated pilot projects in both integrated energy solutions and distributed AI computing. In parallel, Cango continues to operate an online international used car export business through its subsidiary.

About CRDF Cardiff Oncology Inc.

Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.

Share on Social Networks: